Abstract. Detecting new units of pathogenesis in the liver
SCIENTIFIC REVIEWS

GENERAL INFORMATION ABOUT LIVER FIBROSIS
T he trend of continuous increase in liver fi brosis (LF) due to chronic liver damage from alcohol, chronic viral Hepatitis B and C, non-alcoholic fatty liver disease (NAFLD), autoimmune, parasitic and metabolic diseases and less frequently from toxins, drugs (Methotrexate, Tolbutamide), iron, copper and other, requires demand for sensitive, specifi c, non-invasive biomarkers. Chronic liver diseases of various etiology are among the leading causes of morbidity and mortality in the world [1, 2, 3, 4] . The chronic liver disease progresses through various pathological stages that range from mild infl ammation to liver fi brosis and cirrhosis. The assessment of the stage of liver disease is important for the diagnostics, during treatment, as well as for follow-up. Liver fi brogenesis is a dynamic process in which a chronic infl ammation stimulates the production and accumulation of collagen and extracellular matrix proteins. Hepatic stellate cells are the fi rst cells responsible for the preparation of these extracellular matrix proteins. This dynamic process may also include remodeling and regression of fi brous tissue through the breakdown of matrix proteins by protease enzymes [2, 4, 5] . In alcoholism, factors for liver fi brosis and cirrhosis are two pro-fi brotic agents, acetaldehyde and reactive oxygen species (ROS), derivatives of ethanol. Hepatocytes are the primary site of metabolism of ethanol, where these two products are synthesized in abundance, leave outside and enter the stellate cells to activate them. Here, acetaldehyde directly regulates the transcription of collagen and synthesis of the transforming growth factor-beta 1 (TGF-β1). The effect of ROS on hematopoietic stem cells (HSCs) induces the production of infl ammatory mediators which contribute to fi brotic changes in the liver. In NAFLD and its subtype non-alcoholic steatohepatitis (NASH), which are encountered in the metabolic syndrome, obesity, type 2 diabetes, dyslipidemia, and insulin resistance, a central role in fi brosis play adipokines by stimulation of the phagocytic activity [2, 5, 6] . In cholestasis, proliferating epithelial cells of the bile ducts synthesize connective tissue growth factor (CTGF), which stimulates the production of myofi broblasts and deposition of collagen, as well as infl ammatory responses by neutrophils. In chronic viral Hepatitis B and C, the pathogenesis of fi brosis is multifactorial and involves a combination of oxidative stress, liver steatosis, elevated concentrations of iron, increased hepatocyte apoptosis, under the pressure of the viral proteins and viral replication. There is evidence that protein X of hepatitis virus B directly induces the secretion of TGF-β1 from the hepatocytes and thereby contributes to the activation of paracrine factors of stellate cells [2, 5, 7] . The diagnostics of LF is mainly based on: a) liver biopsy; b) imaging methods; and c) serum biomarkers.
NON-INVASIVE DIAGNOSTICS OF LIVER FIBROSIS
Biopsy -Liver biopsy is the oldest and the most accurate method to assess the stage of liver fi brosis. It is considered the "gold standard" and continues to serve as a reference method against which other methods are compared. By biopsy, we obtain information not only about fi brosis but also for infl ammation, necrosis, steatosis, deposits of iron or copper. Optimally biopsy contains 5-11 full portal spaces and refl ects only 1/50000 of the volume of the liver [6, 7, 8] . Liver fi brosis is not a steady process, and biopsies from various areas show different stages of fi brosis. By biopsy, fi brosis, respectively cirrhosis, may be omitted in 10-30% of patients, so it is diffi cult to distinguish between early and advanced cirrhosis. There is a risk of complications ranging from mild pain in the abdomen (in about 20%) to severe intraperitoneal bleeding (occurs in 0.5%) and deaths (frequency 0.009-0.12%). Liver biopsy may be poorly tolerated by patients, especially if it must be repeated. Recently transjugular liver biopsy has been used, which is safer and better tolerated but is available only in specialized centers [5, 8, 9] . Therefore, in the last decade, particular attention is paid to serum biomarkers.
Biomarkers
Biomarkers are defi ned by the Hulka et al. as "cellular, biochemical or molecular changes that are measurable in biological media such as blood serum, tissues or cells". According to more recent data, the biomarker is an indicator of normal biological processes, pathogenic processes or pharmacological response to a therapeutic intervention (Fig. 1) . The biomarker may be a specifi c cell, a molecule, a gene, a product of a gene, an enzyme or a hormone ( Fig. 2 and 3 ) [10, 11, 12, 13, 14] . It can be used for prognosis, cause, diagnosis, progression, regression, or outcome of treatment of a certain disease. Biomarkers are classifi ed by Perera and Weinstein [14, 15, 16] . The development of serum markers is in constant evolution, offering an attractive alternative to liver biopsy for patients and physicians. In recent years, the interest in the identifi cation and description of liver fi brosis by means of non-invasive surrogate markers is on the rise. The advantages of serum biomarkers are many [13, 15, 17] : a) missing invasion; b) no complications; c) small variability; d) can be carried out repeatedly; e) low cost; f) may be performed ambulatory; g) have good sensitivity and specifi city; h) serve to evaluate the effect of therapy (immunosuppressive therapy); i) they applicable to monitoring the disease progression or regression; j) they are not susceptible to false positive results, for example, in patients with infl ammation associated with other diseases; k) they are useful in assessing the stage of fi brosis in patients without clear indication for liver biopsy, such as patients with chronic Hepatitis B or C with normal ALT; l) simple, easily accessible, reliable and validated in different types of liver diseases. Although there is no ideal marker, several markers have been identifi ed as potential useful indicators of fi brosis when used in conjunction with one another. Noninvasive biomarkers also have limitations: a) their main disadvantage is low accuracy for detecting intermediate stages of fi brosis; b) in some of them there may be a lack of hepatic specifi city (i.e. serum levels of hyaluronate may be infl uenced by the presence of renal failure); c) some of them may have been increased in extrahepatic fi brogenesis; d) there is a need for validation based on an international survey; e) they have limited value in assessing the development of complications such as esophageal varices and variceal bleeding. A key question in assessing new non-invasive biomarkers is their validation against the available gold standard (i.e liver biopsy) [11, 17, 18] . Types of biomarkers in liver fi brosis according to pathogenesis [18] Classifi cation of biomarkers for liver fi brosis Biomarkers are classifi ed by Perera and Weinstein. There are two main categories: a) Class I biomarkers for fi brosis or direct biomarkers. They directly correlate with fi brogenesis and fi brinolysis and evaluate the development of the extracellular matrix (ECM). These are extracellular matrix components synthesized and secreted by myofi broblasts, stellate cells, Kupffer cells, macrophages, Th-2 cells, neutrophils and other cells; b) Class II biomarkers or indirect markers of fi brosis. They refl ect changes in liver function and are molecules that are released into the blood when there is an infl ammation of the liver without correlation with the state of the ECM. Direct and indirect markers can be used alone or more frequently in combination. To assess the clinical reliability of markers we often use the area under the curve in ROC analysis (AUC). Below we present briefl y some of the serum biomarkers which are subject to investigation in the last years and thus having clinical application in the diagnostics [7, 11, 12, 14, 18] .
DIRECT MARKERS
These are the various components of the ECM. Direct markers show variable effectiveness in predicting liver fi brosis. They refl ect two main processes -fi brogenesis and fi brinolysis ( Fig. 2 and 3 ) [2, 3, 17, 19, 20 ].
Procollagens: procollagen I carboxy-terminal (PCICP), procollagen III amino-terminal (PCIIINP)
and procollagen IV (PCIV) [5, 9, 12, 15] . These markers are an indicator for deposition of collagen fi bers in the extracellular matrix. PCICP is a major component of the connective tissue. PSIIINP is another major component of the connective tissue, which has been widely studied. Its relative concentration in the basal membrane is greater during hepatic fi brogenesis because of an increase in its serum levels. Serum levels of PCIIINP show a stage of liver fi brosis. During cirrhosis, serum levels of PCIIINP correlate with serum bilirubin. In acute hepatitis, serum levels of PIIINP correlate with aminotransferase levels. It increases in viral Hepatitis B and C, alcoholic liver disease and NAFLD. Its levels correlate with severity of the liver disease. Moreover, reduction of PCIIINP correlates with patient response to treatment with interferon. The major limitation of using PCIIINP determination is that it is not specifi c for hepatic fi brosis and increases also in acromegaly, pulmonary fi brosis, chronic pancreatitis, and rheumatic diseases [7, 16, 18] . Moreover, it shows a lower diagnostic efficacy compared to collagen IV and hyaluronic acid. Collagen IV is a major component of ECM. Unlike the type I and type III collagens, which are processed by proteolysis, this molecule has been deposited intact and its presence in the serum directly affects its degradation. Therefore, investigation of collagen IV is more often used in clinical practice. It increases in liver diseases of different etiologies and its levels correlate signifi cantly with the stage of liver fi brosis. The combination of collagen IV and PIIINP testing increases sensitivity and specifi city. Moreover, the ratio of collagen I/III is also changed from 1:1 in a healthy liver to 1:2 in fi brosis and cirrhosis.
Hyaluronic acid (HA):
This is a mucopolysaccharide glycosaminoglycan, with high molecular weight, a polymer that is present in the joints and liver. It is a component of ECM and is located in the synovial fl uid. It is synthesized by the liver stellate cells. It is the most validated marker that most accurately predicts advanced fi brosis in chronic Hepatitis C and B, steatosis and alcoholic liver disease [9, 17, 18] . Due to its high negative predictive value (98-100%) it may be used alone in clinical practice for the exclusion of advanced fi brosis. In patients treated with immunosuppressive drugs there is reduction of serum levels of HA. High levels of HA may be due to increased synthesis and decreased elimination. In patients with nonalcoholic fatty liver disease, HA is selected for best fi brosis marker with specifi city and sensitivity of 88-95% and 86-100%, respectively. HA is involved in several panels [6, 8, 9, 16] .
MMPs (Matrix Metalloproteinases):
The fi brinolysis or degradation of EMC, is an action which is primarily due to the family of metalloproteinase enzymes. This is a family of structurally related proteolytic enzymes that mediate the breakdown of ECM and basement membranes. The most commonly studied human metalloproteinases are MMP-1, or collagenase, MMP-2 or gelatinase-A, MMP-3 or stromelysin and MMP-9 or gelatinase-B. MMP-1 and MMP-2 are synthesized and secreted by activated stellate cells, MMP-9 are products of Kupffer cells. MMP-1 correlates inversely with histological severity, including necrosis and fi brosis. During liver fi brinogenesis, the expression of MMP-2 is signifi cantly increased. The ratio MMP-1/TIMP1 correlates with the degree of infl ammation. MMP-9 demonstrates inverse correlation with histological severity of chronic Hepatitis C [7, 15] .
TIMPs (tissue inhibitors of matrix metalloproteinases):
TIMPs are secreted proteins that interact with and modulate MMPs activation and operation. TIMP-1 controls the activity of most MMPs and TIMP-2 specifi cally inhibits MMP-2. Тhe level of TIMP-1 signifi cantly correlates with fi brosis, with a sensitivity of 100% but have low specifi city. In chronic Hepatitis C the increase in TIMP-1 and TIMP-2 is associated with progression of fi brosis [7, 9, 15] .
INDIRECT MARKERS
These are routine serum indicators. Serum levels of markers depend on their rate of purifi cation, which is affected by dysfunction of endothelial cells, impaired biliary excretion or renal function. They refl ect primarily the liver function. In clinical practice, it is still adopted to carry out an initial screening of liver fi brosis and/or cirrhosis with simple laboratory tests ( Fig. 2  and 3 ) [20, 21, 22, 23, 24 ].
AST/ALT ratio or AAR:
Serum ALT is one of the oldest markers for assessment of liver function, in particular, the damage of the hepatocytes. Although the serum levels of ALT are affected by many factors, including gender, body mass index, hepatotoxic drugs, and others, this marker is still used because of its good sensitivity and specifi city [23, 24, 25] . In some forms of acute and chronic hepatitis and/or steatosis the ratio AST/ALT is ≤ 1, while in alcoholic hepatitis AST/ALT is often > 2. The negative predictive value of the AAR is 81.3 to 96%, according to data from 2008 [7, 9, 24, 25] . [24, 25] . With a ratio of APRI > 1.5 and AUC of 0.80-0.89 is an indication of advanced fi brosis (respectively F3-F4) and cirrhosis in patients with chronic Hepatitis C and NAFLD and liver transplantation. In a meta-analysis involving more than 8700 patients the summary of AUC values of APRI for signifi cant fi brosis (F2 or more), severe fibrosis (F3-F4) and cirrhosis (F4) were 0.77, 0.80 and 0.83, respectively. APRI fi nds clinical application as a marker for signifi cant fi brosis in patients with Hepatitis C co-infected with HIV. Data from a meta-analysis indicate that APRI can identify hepatitis C-fi brosis only in moderate degree of accuracy (63.74%, p < 0.01) and with a sensitivity and specifi city of 89% and 75% [16, 17, 24, 25] .
AST/platelets ratio or APRI was developed by Wai et al. in 2003
3. PGA index is a combination of prothrombin index, GGT, and apolipoproteins A1. The index PGA is proposed by Poynard at al. in 1977, as a marker for assessing alcoholic liver disease [7, 8, 18] . It has recently been modifi ed as PGAA index by adding α2-macroglobulins. This supplement improves the clinical effi ciency of PGAA test. The test is associated with infl ammation and fi brosis in liver disease. With this extension, the accuracy of the factor increases from 65% for PGA to 70% for PGAA. The increase in serum correlates directly to the degree of fi brosis.
Fibrospect II test combines three parameters:
hyaluronic acid, TIMP-1, and α2-macroglobulin [25, 26] . The test can differentiate mild F0-F1 from severe fi brosis F2-F4 [122] . This is confi rmed in patients with chronic Hepatitis C, where AUC is 0,831 for detection of signifi cant fi brosis F2-F4 [123] . The index has been validated [26] .
5. SHASTA index includes three indicators: hyaluronic acid, AST, and albumin [7, 8] . In a study of patients with chronic Hepatitis C and co-infected with HIV the index showed sensitivity of > 88%, negative predictive value > 94% and specifi city of 100% and positive predictive value of 100% for detecting severe fi brosis (> F3).
Index of Forns: This index is described by Forns et al. in 2002
and is calculated based on the number of platelets, the level of cholesterol and GGT. Some authors include age. With the index of Forns, it is possible to distinguish mild fi brosis (F0-F1) of severe fi brosis (F2-F4) but it is less accurate in the differentiation of fi brosis F2 from F4. The index shows good diagnostic value (AUC: 0.81-0.86) in patients with Hepatitis C and a negative predictive value of 96% to exclude F2 or more severe fi brosis. Index of Forns has been validated in cohorts as predictive index for response to immunosuppressive therapy [7, 8] .
FIB-4:
This index includes the number of platelets, ALT, AST and age. FIB-4 well discriminates both severe fi brosis (AUC 0.85) and cirrhosis (AUC 0.91).
Recently, this marker has been assessed in patients with chronic hepatitis B and 71% sensitivity and 73% specifi city for diagnosing ≥F2 fi brosis is found. It is reliable in determining the NAFKD and shows sensitivity and specifi city of advanced fi brosis (F3-F4) of 74-85% and 65-71%, respectively [6, 7, 11 ].
Fibrotest or Fibrosure test (in Europe and
America, respectively): This test is the most widely validated indirect serum marker in Hepatitis B and C and NAFLD [62, 63] . Five parameters are used: total bilirubin, haptoglobin, GGT, α2-macroglobulin and apolipoprotein-A1. Furthermore, it may include age and gender. In a detailed review including 9 studies with 1679 patients, it has established an excellent discrimination for identifying cirrhosis (summarized AUC = 0.90) and to a lesser extent for identifi cation of signifi cant (≥ F2) fi brosis (AUC = 0.81). However, the conclusion is that non-invasive tests are not ready to replace liver biopsy yet. Later in a study with 6378 subjects, the mean standardized AUC for diagnose signifi cant (≥ F2) fi brosis is 0. [16, 17, 18, 28, 29, 31, 32] . The advantage of this test is that it is automated and offered by different companies on the market.
